Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel

Coronary Artery Disease

Volumn 20, Issue 3, 2009, Pages 207-213

  Oestreich, Julie H ^a   Holt, John ^a   Dunn, Steven P ^a   Smyth, Susan S ^a,b   Campbell, Charles L ^a,b   Charnigo, Richard ^a   Akers, Wendell S ^c   Steinhubl, Steven R ^a,d,e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

^c LIPSCOMB UNIVERSITY   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e Medicines Company   (Switzerland)

Author keywords

Adenosine diphosphate; Blood platelets; Clopidogrel; Coronary artery disease; Platelet aggregation; Purinoceptor P2Y12

Indexed keywords

CLOPIDOGREL; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PURINERGIC P2 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; AGED; ANALYTIC METHOD; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MALE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; TIME;

ADENOSINE DIPHOSPHATE; AGED; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; TICLOPIDINE; TIME FACTORS;

EID: 66349118978     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328329924b     Document Type: Review

References (33)

1. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420. (Pubitemid 35340537)
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502. (Pubitemid 32758501)
3. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967-1971.
4. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92:641-649.
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913.
6. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111:2560-2564. (Pubitemid 40740853)
7. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783-787. (Pubitemid 36603418)
8. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45:246-251. (Pubitemid 40094733)
9. Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999; 25 (Suppl 2):9-14. (Pubitemid 29350285)
10. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48:1339-1345. (Pubitemid 44436814)
11. Kastrati A, Von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110:1916-1919. (Pubitemid 39331901)
12. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099-2106. (Pubitemid 40577905)
13. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:e166-e286.
14. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115:708-716. (Pubitemid 46294761)
15. Von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28:1814-1819. (Pubitemid 47236637)
16. Angiolillo DJ, Bernardo E, Palazuelos J, Desai B,Weisberg I, Alfonso F, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008; 99:161-168.
17. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008; 121:463-468. (Pubitemid 351174278)
18. Steinhubl S, Roe MT. Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovasc Drug Rev 2007; 25:188-203. (Pubitemid 47039093)
19. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19:119-124. (Pubitemid 351302375)
20. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827-1832. (Pubitemid 41579803)
21. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4:542-549.
22. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005; 111:1153-1159.
23. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
24. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6:54-61.
25. Weerakkody GJ, Jakubowski JA, Brandt JT, Payne CD, Naganuma H, Winters KJ. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 2007; 12:205-212. (Pubitemid 47305433)
26. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
27. Storey RF,Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13:407-413. (Pubitemid 35346941)
28. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852-1856. (Pubitemid 350017792)
29. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44:2133-2136. (Pubitemid 39576031)
30. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939-943. (Pubitemid 43312753)
31. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51:1404-1411.
32. Angiolillo DJ, Costa MA, Shoemaker SB, Desai B, Bernardo E, Suzuki Y, et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008; 101:440-445. (Pubitemid 351210628)
33. Neubauer H, Lask S, Engelhardt A, Mugge A. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99:357-362. (Pubitemid 351230967)